Asciminib is a new inhibitor that zeroes in on the BCR-ABL tyrosine kinase. It’s meant for CML patients who’ve tried other treatments but didn’t work. It works by blocking a specific part of the ABL protein called the myristoyl pocket.
You can get it as 20 mg or 40 mg tablets, both with a film coating. For adults, the recommended dose is 80 mg a day—either one 40 mg tablet once, or two 20 mg tablets twice a day. The tablets come in bottles with 60 pills each.
